Around 4,000 formulations (or a third of all compunds sold in Egypt) are currently in short supply — if sold at all — as a result of manufacturers pulling the plug, said Health Minister Ahmed Rady at a parliamentary inquiry. Most of the medicines are priced under EGP 30, necessitating the decision to increase their prices 20%, AMAY reports. Companies that fail to produce any one compound within three months of the price hike being authorized will have their licenses revoked, said Rady. He did not elaborate on last Thursday’s decision to cap the price increases at EGP 6, a decision which led to a major outcry from producers. The Federation of Egyptian Industries is expected to meet with Rady this week to formally protest the decision, according to Al Borsa.